Table 2 In vitro antitumor activity of compounds 1–6
Compounds | A549 (µM) | HT29 (µM) | MDA-MB-231 (µM) | PSN1 (µM) |
|---|---|---|---|---|
1 PM100117 | ||||
 GI50 | 1.52 | 3.04 | 2.66 | nd |
 TGI | 1.84 | 3.23 | 2.79 | nd |
 LC50 | 2.22 | 3.61 | 2.97 | nd |
2 PM100118 | ||||
 GI50 | 2.24 | 1.92 | 1.73 | nd |
 TGI | 3.13 | 2.81 | 2.75 | nd |
 LC50 | 4.28 | 4.09 | 4.16 | nd |
3 from mutant gonP8 − | ||||
 GI50 | >8.40 | >8.40 | >8.40 | >8.40 |
 TGI | >8.40 | >8.40 | >8.40 | >8.40 |
 LC50 | >8.40 | >8.40 | >8.40 | >8.40 |
4 from mutant gonP8 − | ||||
 GI50 | >8.40 | >8.40 | >8.40 | >8.40 |
 TGI | >8.40 | >8.40 | >8.40 | >8.40 |
 LC50 | >8.40 | >8.40 | >8.40 | >8.40 |
5 from mutant ∆gonCP | ||||
 GI50 | 0.38 | 0.13 | 0.71 | 0.90 |
 TGI | 0.54 | 1.80 | 0.83 | 0.96 |
 LC50 | 0.77 | 2.50 | 1.03 | 1.03 |
6 from mutant ∆gonCP | ||||
 GI50 | 1.11 | 3.39 | 2.60 | 2.80 |
 TGI | 1.17 | 4.30 | 2.80 | 3.00 |
 LC50 | 1.24 | 5.48 | 3.00 | 3.19 |